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This article examines the reﬂexive, biosocial nature of genomic meaning making around race, drawing on
discourse analysis of 732 articles on genomics and race published from the years 1986e2010, in-depth
interviews with 36 of the world’s most elite genomics researchers, interviews with 15 critics, policy-
makers, and trainees involved in debates over race, and participant observation at a core genotyping
facility that specializes in ancestry estimation. I reveal how biomedical researchers identify with, value,
and make sense of the taxonomies they construct. My analysis goes beyond a consideration of instru-
mental rationales to analyze the experiential and political motivations that shape how researchers get
involved in racial ethical dilemmas. I theorize taxonomic practice as a reﬂexive form of biosociality,
a conscious shaping of social notions about biology and race to produce a future that researchers
themselves want to live in. I demonstrate how reﬂexive biosociality paradoxically leads researchers to
advance social explanations for race while investing in genomics as a solution to racial quandaries.
 2011 Elsevier Ltd. All rights reserved.Introduction
In recent decades, the urge to understand how humans vary
from one another at the level of DNA has produced biomedical
investigation into the genomics of race. The study of genomics has
resulted in a dizzying back-and-forth stance on racedﬁrst denial of
any racial difference at the level of DNA, to later focusing attention
on these differences (Reardon, 2005). Across the ﬁeld of genomics,
leading labs have tested the biological validity andmedical utility of
race with each newly invented biomarker platform and informatic
program (Bliss, 2012). International genome projects like the
Human Genome Project, Human Genome Diversity Project, and
International HapMap Project have gone from avoiding race
wholesale to embracing it; sampling DNA by common lay taxon-
omies (Bliss, 2009). In 2005, the ﬁrst race-based medicine was put
to market (Kahn, 2008; Lee, 2007), creating a stir in the genomic
community. Examining all our DNA to understand the common
illnesses and variation that affect humanity, genomics uses patterns
of shared ancestry within the human species to redeﬁne human
taxonomy and question the limits of prior notions of difference
(Fujimura & Ramagopalan, 2011).
This renewed interest in the biology of race is surprising given
that representatives of an array of natural and social sciences,
including leading geneticists, once whole-heartedly denounced
prior racial biomedicine. For over half a century, internationalAll rights reserved.governing bodies and academic organizations elaborated state-
ments, policies, and theories deﬁning race in terms of social and
political dynamics only (see AAA, 1998; Duster, 2003; UNESCO,
1950, 1952). In an age when it seems academic common sense
that race as a category is socially constructed, how is a genomics of
race possible?
This article explores the resurgence of racial biomedicine in
terms of reﬂexive biosociality: researchers’ conscious effort to
create analytics that contribute to a future they themselves want to
live in. Genomicists who experience the social reality of race have
a vested interest in scientiﬁcally “getting race right.” They oscillate
between policy frameworks and experiential rationales to fashion
taxonomies that square with dominant values about minority
inclusion and medical equality. Most use a racial taxonomy when
they believe it can help racial minorities. These reﬂexive repre-
sentation processes allow researchers to produce a social order that
beneﬁts themselves and their kin, while offering avenues for race-
based sociality that make sense in the current redress-focused
context. This leads to a science in which researchers simulta-
neously posit race as real but not real. Researchers paradoxically
advance social explanations for race, while asserting genomics as
a plausible solution to racial dilemmas.Genomics at the Surface
In the past decade, genomic investigation into race has spawned
a notable public controversy (Braun, 2002; Hunt & Megyesi, 2008).
A vigorous debate followed President Clinton’s celebratory remarks
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to emerge from this triumphant expedition inside the human
genome is that in genetic terms, all human beings, regardless of
race, are more than 99.9 percent the same” (Ofﬁce of the Press
Secretary, 2000). While leading genomicists rallied to make
corroborating statements (Angier, 2000; Chandler, 2001),
consensus on the genome’s proof-positive meaning for race
faltered as early as 2001 when a drug editor at the New England
Journal of Medicine claimed that race corresponded with the
genomics of drug response. A number of researchers published
contrasting opinions in the ﬁeld’s leading biomedical journals
(McLeod, 2001; Rothstein & Epps, 2001; Schwartz, 2001; Wilson
et al., 2001; Wood, 2001), while journals hosted special issues
devoted to proving the un-biological nature of race (see, for
example, Nature Genetics December 2001; The Pharmacogenomics
JournalMarch 2001; Scientiﬁc American June 2003). By mid-decade,
major biomedical journals had developed editorial recommenda-
tions for reporting with racial classiﬁcations (Litt, 2001; Nature
Genetics, 2001, 2004; Rivara & Finberg, 2001; Steele, 2002;
Winker, 2004). While most genomicists who have discussed the
meaning of race have made strong statements against its biological
basis, a few prominent researchers have maintained that there are
serious biological aspects of race that should not be ignored.
Questions of how genomic researchers should operationalize
race in efforts to include minorities in biomedical research and
public health frame the ﬁeld’s controversy. U.S. federal policy
mandates that researchers use federal classiﬁcations to structure all
publicly funded research. This policy emerged in the late 1980s,
when the Department of Health and Human Services commenced
an aggressive campaign to implement the federal race standards
designated in the Ofﬁce of Management and Budget’s Directive No.
15 (Stoto, Behrens, & Rosemont, 1990:51). Issued in 1977, Directive
No. 15 required all government ofﬁces and agencies to monitor
patterns in racism, segregation, and racial disparities in voting
practices by tabulating American Indian or Alaska Native, Asian or
Paciﬁc Islander, Black, and White participation (OMB, 1978). After
a hard-won battle to convince the federal government that women,
children, and minorities were also ignored by the one-size-ﬁts-all
health system, in 1986, the National Institutes of Health began
drafting its ﬁrst minority inclusion policy (Epstein, 2007). Being
conscious of race was to become a norm and standard across
biomedicine, with corollary support in the wider public (Bliss,
2009). Seven years later, the National Institutes of Health issued
the Revitalization Act, a statute setting strict guidelines for the
inclusion and surveillance of women and minorities in clinical
research and clinical trials (NIH, 1993). In 1993, the Center for
Disease Control and Prevention also drafted “Use of Race and
Ethnicity in Public Health Surveillance” statement (CDC, 1993, also
see CDC, 1999). By 1998, the Food and Drug Administration ruled
that all new drug applications must “present effectiveness and
safety data for important demographic subgroups, speciﬁcally
gender, age, and racial subgroups” (FDA, 1998) and the Surgeon
General’s Ofﬁce began administrating its Healthy People decennial
program by Directive No. 15 classiﬁcations (HHS, 1998). Since the
turn of the century, these health agencies have revitalized these
policies with implementation mandates sensitive to the unique
challenges faced by researchers working in their domains (NIH
2000, 2001; FDA 2003, 2005). Thus, researchers must take federal
research inclusion aims into account from the earliest stages of
research design.
Continued controversy despite clear policies on how researchers
should work with the federal taxonomy, and ostensive closure of
prior debates, has motivated some social scientists to question how
genomic researchers conceptualize and apply race in the lab and
clinic. Recent empirical investigation has shown that researchers ofvarious ranks operate without clear deﬁnitions of racial variables
and that they fail to critically examine their inconsistent practices
(Fullwiley 2007a, 2007b; Hunt & Megyesi, 2008; M’Charek, 2005;
Tutton, 2007; Tutton & Corrigan, 2004). Interviews with genome
project leaders and journal editors have shown that the ﬁeld’s
gatekeepers are reluctant to see critical race policy as important to
their role (Outram & Ellison, 2006; Smart et al., 2008) and they
ignore the political dimensions of their work (Reardon, 2005).
Ethnographies of leading pharmacogenomics laboratories and
population-based biobanks have also shown that researchers
uncritically align federal inclusionary standards with genomic
population categories to produce a system of research wherein
research populations are stratiﬁed by race and then targeted for
race-based cures (Fullwiley, 2007a, 2007b, 2008; Montoya, 2011;
Smart et al., 2008; Tutton, 2007; Tutton & Corrigan, 2004;
Whitmarsh, 2008). Some studies have suggested that lead inves-
tigators allow market interests to instrumentally guide their
research (Fullwiley 2008; Nelson, 2008a, 2008b). Asking
researchers directly about their deﬁnitions of race has provoked
uncomfortable silences and bashful laughter, to no avail of a critical
working model (Fullwiley, 2007a, 2007b; Tutton, 2007; Tutton &
Corrigan, 2004; on working models of race, see Morning, 2009).
Two researchers have been shown to overtly draw on their personal
values about race to guide the classiﬁcation process (Fullwiley,
2008; Nelson, 2008a).
The present study, consisting of interviews with many of the
ﬁeld’s leaders, ﬁnds that genomic elites are conscious of their role
as knowledge gatekeepers and are proactively aligning their
taxonomies with broader ethical values on race. As members of
a biomedical system that rewards inquiry into minority health and
health disparities, these researchers use their positions to instigate
research that may shape the world’s knowledge about race (Moore,
2008). Though genomic researchers view variation from a medical
perspective, they nevertheless interpret the world around them
from within a matrix of racialized values, conventions, and under-
standings. Researchers reﬂexively draw from memories of preju-
dice and discrimination to create an antiracist biomedicine, and
interpret and implement their values-based framework through
the lens of racial justice that dominates biomedicine today. They
enact their beliefs about prejudicial treatment, racism, and racial
inequality through their inquiry into and representation of race and
their use of racial taxonomy.
These processes of representation can be viewed in terms of
biosociality. At the turn of the century, Rabinow predicted the rise
of a mode of intersubjectivity where “groups formed around
[genomic classiﬁcations would] have medical specialists, labora-
tories, narratives, traditions and a heavy panoply of pastoral
keepers to help them experience, share, intervene in, and ‘under-
stand’ their fate” (Rabinow, 1996:244). Biology-based intersubjec-
tivity has indeed advanced as states have progressively applied
genomics in the administration of health welfare (Epstein, 2007;
Petryna, 2002; Rose, 2007). The U.S. government’s move to
publicly fund health disparities research has entwined with its
incorporation of genomic technologies into America’s basic
research institutions (Bliss, 2012). Epstein (2007) has shown that
the fortiﬁcation of inclusionary policies ensures that the new
genomic citizenship will continue to be constructed within
a racialized system of health governance. Bolnick et al. (2007) have
described theways consumermarkets intersect with state efforts to
produce race-targeted products, services, and research. Abu El Haj
(2007) argues that biosociality around race is increasingly
attuned to the logic of risk that dominates genomic biomedicine.
Building on this research, I place researchers and their subjec-
tivity at the center of biosociality. I show that genomic elites make
choices that contradict a strict biologically objective rationale,
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criticize race and just as ﬁercely defend its role in medical research,
because they see race as being biologically questionable yet socially
salient. In this sense, this genomic biosociality is reﬂexive bio-
sociality. Researchers consider ofﬁcial taxonomies and the
discourses of race at hand in critical ways, because they see
themselves as the stewards of the public’s vitality (Fullwiley, 2008;
Rose, 2007). They increasingly engage in minority inclusion
campaigns and genomic health disparities research to promote
their racial values and to create a social system that can best serve
themselves and their loved ones.
This is not to say that careerism, ﬁnancial considerations, and
other forms of self-interest are not entwined with reﬂexive bio-
sociality. Genomic elites are agents of biotechnology development,
pharmaceutical research, and clinical medicine, and are thus con-
cerned about proﬁtability and political survival in complex ways.
Yet, the practical world in which these scientists operate is inex-
tricable from a social world eager for innovative solutions to social
problems (Rabinow, 2003). Researchers’ iterative assertions of
preoccupations with youth and family present a speciﬁc kind of
biosociality that relies on personal enthusiasm and open moral-
izing about the work at hand (Shapin, 2008). Just as patients and
research subjects have become politicized in the contemporary
context of engaged health activism (Novas and Rose, 2000),
biomedical researchers are interpreting their surroundings through
a politically charged set of values and using their positions to shape
the future.
This model for understanding biomedical research is different
than prior understandings of biosociality in two important ways.
Rabinow devised the concept to represent an emergent kind of
sociality formed around new biotechnologies. According to him,
individuals begin to socialize around the new forms of biological
knowledge and medical expertise that increasingly populate the
public sphere. As people put greater weight on the biomedical
signiﬁcance of their existence, sociality becomes infused with “bio”
interpretations (Rabinow, 1996). Others have followed Rabinow in
speciﬁcally focusing on social action pertaining to health
consumers and patients (Novas, 2006; Novas & Gibbons, 2007;
Rose, 2007). By contrast, my conceptualization of biosociality
apprehends social action pertaining to researchers, who are also
the stakeholders and beneﬁciaries of new knowledge and exper-
tise. As such, reﬂexive biosociality shows us that biosociality is not
simply about the production of new subjectivities and intersub-
jective ties around new objects of biomedical research. Rather, the
subjects of biomedicine, biomedical researchers themselves, also
craft their subjectivity around new objects of research. Researcher
identities are produced dialectically with the racial knowledge that
they produce.
Reﬂexive biosociality is also different from prior conceptuali-
zations, because it tackles social formations taking shape between
emergent and residual epistemes (Williams, 1991). Moving beyond
the idea that biosociality is a mere matter of new disease categories
displacing old forms of taxonomy, my conceptualization shows that
concepts of race also shape emergent frameworks. In fact, indi-
viduals seize on new biotechnologies in order to createmore robust
notions of race, gender, and other longstanding, institutionalized
classiﬁcation systems. This conceptualization, thus, provides
a more dynamic understanding of the objects around which people
biosocialize and the modes by which they biosocialize.
Though recent ethnographies of genomics have edged toward
taking scientist subjectivity and epistemic intersections into
account, none have fully explored these aspects. While Reardon’s
(2005) research into the Human Genome Diversity Project has
illuminated how project scientists’ ignorance about racial
inequality and privilege led to the project’s demise, and Montoya(2011) and Smart and colleagues (2008) have shown that racial
ignorance has informed the ways that scientists and editorial
gatekeepers operationalize ofﬁcial standards, none have examined
the manifest political choices that scientists make or the values
they consciously draw on. Nelson (2008a, 2008b) and Fullwiley
(2007a, 2007b, 2008) have characterized how individual scien-
tists have intentionally shaped the broader public biosociality
around race. For example, Nelson has revealed the ways one Afri-
caneAmerican entrepreneurial scientist has inﬂuenced Afri-
caneAmerican biosociality with his commercial framing of
blackness and diaspora (Nelson, 2008a, 2008b). Studying a Latino
scientist that manipulates data to produce Latino-speciﬁc phar-
macogenomics interventions, Fullwiley has described the minority
scientist as a spurious “shepherd” for other minorities (Fullwiley,
2008:726). Yet, neither addresses patterns across biomedical
research. Studying a collection of the ﬁeld’s most inﬂuential sci-
entistsdminority and otherwise racializeddI show that
researchers across a ﬁeld reﬂexively use their science to attempt to
produce social change.
Data and methods
This analysis is based on semi-structured, hierarchical inter-
views with 36 widely distributed members of the ﬁeld’s profes-
sional elite. This researchwas supported by NSF grant SBE-0727360
with IRB approval from the New School of Social Research. It is part
of a larger study on genomic racial biomedicine that involved
content analysis of 732 articles on genomics and race published
from the years 1986e2010, in-depth interviews with 51 researchers
and social critics involved in debates over race, and participant
observation at a core genotyping facility that specializes in ancestry
estimation. Though subjects are stationed globally and all conduct
multi-sited research, all interviews were conducted in subjects’
Canadian or U.S. headquarters. Of the present subsample, all but
ﬁve researchers were between the ages of 35 and 55. Five are
women. I do not provide racial tabulation for reasons discussed
below. Since these researchers are publicly recognizable, I obtained
consent to using subjects’ names and institutional afﬁliations.
The researchers constitute a purposive core-set sample of senior
and lead scientists listed on the publications of the major global
genome projects and international epidemiological cohort studies
of the genomic era, and inaugural reports of the ﬁeld’s deﬁning
technological breakthroughs (see Collins, 1992). They are the
founding directors and lab chiefs at the world’s leading sequencing
centers, chief ofﬁcials of the ﬁeld’s professional societies, and
editors of the most venerated venues for genomic research publi-
cation. Most are also high-ranking members of leading pharma-
ceutical or biotechnology ﬁrms. Because genomics is a highly
concentrated capital-intensive science, these researchers control
the vast majority of resources in the ﬁeld. Beyond the high proﬁle
human variation and biomedical studies for which they are famous,
these researchers are also responsible for the ﬁeld’s basic inquiry
into plant and animal genomics, the genomics of microorganisms,
and synthetic genomics.
Between April 2007 and June 2008, I conducted digitally
recorded interviews at a number of locations in and around
researchers’ North American headquarters. I invited researchers to
participate in the study with a brief email noting my interest in race
and human variation after the Human Genome Project. I was aware
that any mention of race would likely bring out a measure of
impressions management around the subject’s racial values, so I
geared my interview questions to the practices in each researcher’s
lab, used records of each researcher’s activities to learn about their
social and biomedical responsibilities, and observed many in an
array of work-related contexts. Interviews consisted of
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observation of the technologies used in individual labs and visits to
surrounding genotyping facilities that provide services to these
researchers. Post-interview observation included up to 8 h of non-
recorded shadowing and dialogue. All recorded material was
transcribed verbatim in its entirety and manually coded.
Rather than seek a truth-value to their claims, I take themes in
self-presentation itself as a valuable kind of evidence (Goffman,
1959). Narrations, especially ones that involve recollections of the
past, are always rooted in contemporary concerns (Danto, 1985).
Therefore, rather than communicate a veriﬁable truth, these
narrations signal broader normative trends, ethical frameworks,
and moral dilemmas that presently affect individuals. In what
follows, I present the ways genomicists draw on memory and
marshal past experience to “account for themselves”
(Hermanowicz, 2009) and “organize their complex pasts to present
a coherent self-identity” (Hermanowicz, 1998). I triangulate
researcher narrations with their personal histories and present
protocols to show howelite genomic researchers are conceiving the
biosocial future.
Research ﬁndings
I found that, contrary to the overwhelmingly race-critical tone of
the ﬁeld’s mainstream debate, researchers have been reinvesti-
gating the likelihood of a biological basis for race with each new
genomic advance (Bliss, 2012). Also, leading researchers are deeply
ambivalent about the role of racial taxonomy in genomic medicine
that is not directly focused on redeﬁning race. A large majority
explained that racial taxonomy is useful for inclusionary purposes,
respecting the self-determination of minority research subjects,
and addressing health disparities. Yet, an equally large majority
strongly criticized its use in the lab and clinic.
Still, the most intriguing pattern inmy study of elite genomicists
was their preoccupation with the subjective and political implica-
tions of their research. Scientists answered all of my questions
about basic research practices with thick descriptions of their
personal motivations, social concerns, and political interests. The
narrations that follow reveal how scientists reﬂexively make sense
of their research by considering a range of social and ethical issues
that arise in a biosocial world. In doing so, racial experiences and
values entwine practical demands for research taxonomies to
create a powerful commitment to biologically redeﬁning race and
the social ﬁeld.
Thinking through the present with the past
Before asking a single question from my interview schedule,
many researchers I met shared personal stories of their ﬁrst racial
experiences. They relayed emotionally elaborate tales of childhood
events, workplace encounters, and people along the way who
changed the way they thought about race and variation and made
them want to know “what makes people different,” “what was the
basis of why people are in different groups,” and “why I was in the
race that I am.” This should not be surprising, since genomicists,
like everyone else, undergo processes of racialization. Yet, the
consistent intensity revealed in this array of interviews shows that,
when faced with the task of explaining their work, researchers use
past experiences to make sense of their present-day practices and
present day ﬁndings to make sense of their own racial pasts.
Some conﬁded having a deep-seated childhood curiosity about
race as a result of growing up in the segregated Southern U.S.
Typical among the Southern researchers I met was a heightened
sensitivity to the difﬁculties in making sense of racial discrimina-
tion. As Howard University’s Georgia Dunston stated:.it seemed if we could understand what made [blacks]
different then maybe we could be all alike, so that the prob-
lemsdespecially the negative things with folks who were in
groups that seemed to be bad (as we were told)dif we under-
stand what made us this way, maybe we could change them.
Dunston went on to found America’s premier genomic institute
focused on African-American health: Howard’s National Human
Genome Center. The National Human Genome Center’s mission
statement reads:
The mission of the National Human Genome Center is to explore
the science of and teach the knowledge about DNA sequence
variation and its interaction with the environment in the
causality, prevention, and treatment of diseases common in
AfricaneAmerican and other African Diaspora populations
(Howard University, 2011).
Armed with this explicitly racial outlook, Dunston has attempted
two genome sequencing projects targeted toward African-American
DNA research: the Genomic Research in African-American Pedigrees
Project and the Genomic Research in the African Diaspora Project.
She has frequently been quoted as arguing for a genomics that
focuses on African-American health and the relationship of racial
experiences to genetics (see, for example, Dunston, 2011; Goldstein
&Weiss, 2003). Her story exposes how racial perplexity can serve as
the foundation for subsequent biomedical inquiry and one’s bioso-
cial vision of the genomicist’s role. Likewise, it suggests that
researchers use situated rationales to think through their career
paths. Understanding race is not just about biomedicine; it is about
being able to make sense of one’s own life.
Researchers who grew up outside of de jure segregation stressed
the impact de facto segregation had on their future work. One
population scientist told of his entry into a minority-dominated
urban university and his successive commitment to inner-city
public health. Another researcher explained seeking out fellow-
ships in African-American communities before widening his basic
research to studying the differences in immigrant African and
African-American populations. Among the MD/PhD researchers I
met, stories of medical service in de facto segregated zones were
rampant. As Joanna Mountain of the Google-backed personal
genomics company 23andMe phrased it, these researchers saw
themselves as “concerned about the impact of racism ﬁrst” before
entering the ﬁeld. Their present construction and application of
human taxonomy is bound to concerns about the best way to
represent people and address the social and medical needs of
communities in which they have worked and lived. In doing so,
researchers build a biosocial solution to the social and political
problems of inequality and the conceptual problems of race.
All but one of the elite researchers in this study revealed the
effect familial racial experiences have had on racial beliefs.
University of California-San Francisco’s Esteban Burchard, an
asthma researcher who self-identiﬁes as Latino, related how his
mother’s experiences impacted his own:
My mom was really hard working and my grandmother also
worked very hard. She was very smart and I always thought, I
still think to this day, that she didn’t get her due credit because
of her racial background. I still believe that if she was white she
would have been much more successful, but she looks black.
Burchard later described how his mother foretold that his
“lighter skin” privilege would take him out of the racial ghetto he
grew up in:
And she told me once when I was very young, I must have been
like seven, she said, “You are going to be able to go places where
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today. Because of who you are and your abilities, you can go
through certain scenarios back and forth, kind of like a ﬁsh going
through a big net. Some ﬁsh can go back and forth while other
ones will get caught. And she toldme very young that I would be
able to do that. And she was right.
Burchard and other minorities spoke about including racial
minorities in their research, and studying minority health, as a way
of leveling the social playing ﬁeld that created trauma for them-
selves and their own families. Researchers also spent time talking
about their children, their children’s experiences, and the kind of
world they envisioned for them. They described their efforts at
understanding genomic variation as a battle for redeﬁning race.
Thus, for personal and social reasons, the idea of relegating its
inquiry into the dustbin of history is not an option. Rather,
researchers look to biosocial stewardship through genomics.
Though, in the interests of maintaining race as an open question,
I did not ask them to convey a racial afﬁliation or discuss the racial
backgrounds of their family members, most of the researchers I
interviewed offered up this information without prompt. One
quarter told me that they were “multiracial” or belonged to
a multiracial family. Members of multiracial families, including
white scientists who have children that identify as nonwhite,
openly discussed the inﬂuence of racial experiences in their present
day lives, showing family photos and reﬂecting on their children’s
racial identities and experiences, further evincing the role of
personal matters as one aspect of racial sense making.
Nearly half of those I interviewed reported Jewish origins and
discussed race in terms of anti-Semitic experiences. These Jewish
researchers were quick to link past anti-Semitism to present day
racism affecting themselves and North American minorities. Some
recounted racial discrimination in their own lives such as being set
apart from others at school, while others explained their ancestors’
hardships in Nazi Europe and Eastern European pogroms. The
history of twentieth century eugenics and Nazi “racial hygiene”was
important to these researchers’ worldviews and pedagogies. For
example, two Harvard researchers, Joel Hirschhorn and David
Altshuler, have created a lecture on the school’s broad history of
racial abuses for their Human Genetics course. Others have taken
part in the passage of protective policies such as the Genetic
Information Non-Discrimination Act in order to protect themselves
and their loved ones from potential harm.
Finally, a number of participants in this study were foreign born.
These researchers were vocal about their acculturation and racial-
ization experiences in North America. All but one of the foreign
born researchers I interviewed were married to U.S. or Canadian
citizens and had multicultural, if not multiracial, families. Those
who have been ascribed a minority racial identity or have family
members who have been racialized as minorities were particularly
critical of the racist legacies of genetics and wanted to, as the
National Human Genome Research Institute’s Charles Rotimi put it,
“inform the whole notion of identity” with their research. They
revealed a heightened self-consciousness based on a deep suspi-
cion of ofﬁcial taxonomies in a variety of contexts. Like their
colleagues doing comparative research on immigrant populations
and domestic racial minorities, foreign-born researchers felt it was
their job to problematize commonsense taxonomies, but they also
mobilized racial taxonomy in the interest of minority inclusion.
Thus, they interpreted their work on race as socially advantageous
to minorities around the world.
All in all, these biomedical elites present the relevance of racial
memory and experience to everyday scientiﬁc practice. Each views
the world and their taxonomic responsibilities through a histori-
cally contingent racialized lens. Reﬂections on their own identitiesand the classiﬁcations most salient to their personal lives are at the
forefront of the way they speak about race. Researchers interpret
their own struggles as they think through the very object of their
research.
Putting experiences and values to work
Nearly everyone I interviewed referred to the troubled history of
eugenics at least once during our conversations. Researchers also
avidly denounced the racist values that shaped biomedicine prior to
eugenics. Many referred to the study of “black diseases,” “Negro
problems,” and thenetworks ofpolitical prestige and investment that
fueled past research. Several researchers spoke speciﬁcally about
Johann Blumenbach’s “varieties,” Carl Linnaeus’s taxonomy, and the
hegemonic reach of scientiﬁc racism over biomedicine and society
today. Insteadof relegating these ideas to thedistant past, researchers
talked about the shadow they have cast over contemporary
biomedicine. Though they described eugenics as, in thewords of one
genomicist, their “intellectual ancestry,” they optimistically spoke of
these legacies as something that could be rectiﬁed through better
genomic deﬁnitions of race. In order to have the biosocial future they
envision, these researchers believe that biosocial medicine is neces-
sary. Researchers see the need for the ﬁeld to utilize its technology to
solve any dispute about race’s real biological meaning (see, for
example, Burchard et al., 2003; Kumar et al., 2010; Tang et al., 2005).
All the researchers I interviewed devise mechanisms for
promotingminority inclusion in genomic research. They agree with
the government’s premise that biomedical research has historically
been Eurocentric. They revile the lackadaisical attitude toward
minority recruitment in all biomedical research, but are especially
concerned that genomics guide other ﬁelds in matters of inclusion.
Rotimi offered critical comments about a study that claimed that it
couldn’t include minorities exemplify this sentiment:
Over about a year or two years, periodically they only called in
one or two families.
And somebody says, “We can’t or we don’t want to participate,”
ebut forgetting that the reason maybe you’re not successful is
that you don’t understand this community. You don’t have
somebody that they can relate to, to participate in a study like
this. And of course you may also have a history of collecting this
kind of information and never going back to them with your
results. And so why should they come again?
Rotimi desires more minority representation in the subject and
researcher populations. He implies that a minority subject’s inter-
ests will be better attended to if the researchers share similar
background experiences. His strategy creates a dual project of
recruiting scientists of color and creating a biosocial group in the
image of the recruiter. At the National Institute of Health, Rotimi
launched a center dedicated to genomic research into racial health
disparities. The Center for Research on Genomics and Global Health
(formerly the Center for Genomics and Health Disparities) scans the
genomes of people of African descent for biomarkers relevant to
major diseases like diabetes and hypertension in studies that are
minority-led according to this anti-Eurocentrism vision.
Another genome project founder explained this principle in the
reverse. Luigi Luca Cavalli-Sforza associated lingering Eurocentrism
with the high representation of European Jewish ancestry among
genomic colleagues, saying Ashkenazi Jews were over-studied at
the expense of even Sephardic Jews. In the process of collecting
samples for the Human Genome Diversity Project, Cavalli-Sforza
attempted to focus on undersampled populations like indigenous
South and East Asians. Strategies like these show how genomic
researchers operationalize inclusion, both in terms of who
comprises the ﬁeld and gets researched.
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often start by oversampling racial minorities. David Hinds, formerly
of Perlegen Sciences, the main industry-based participant in the
International HapMap Project, explained:
If you just sample people at random in the United States, you’ve
got 7% Asians and 9% AfricaneAmericans and 6% Hispanic
people. But with those groups you’re not going to have enough
of them to be able to detect small genetic effects, and most of
your analyses are going to end up being restricted to the subset
of European people.
Perlegen’s multi-population studies have oversampled by clas-
siﬁcations akin to the Census taxonomy (see, for example, Hinds
et al., 2005; Patil et al., 2001).
Genomicists also try to be inclusive by creating drug studies and
biotechnologies that target minorities. They pride themselves on
their politically sensitive relationships with groups that they can
use as proxies for the larger population, while emphasizing their
ability to move resources directly to minority groups. As Rick
Kittles, an expert on African populations and CEO of a genetic
genealogy company, said:
When I go into West Africa people see themselves in what I do
and I make sure of that. I’m very sensitive, even in the studies
that we do in the African-American populations. I think that
there is a level of fraternity and actual egos that create barriers
to sample collection.
Kittles has been extremely successful at building a large African
populations database for use in his research at the University of
Chicago and his company African Ancestry, Inc. Kittles was one of
several who critiqued prior sciences for sampling DNA from
minority groups and giving nothing in return.
It is important to note that pharmacogenomics and biotechno-
logical development, where scientists cross the for-proﬁt and non-
proﬁt divide, can lead to a narrow, proﬁt-based deﬁnition of
biosocial reciprocity. For example, instead of giving back tangible
resources, African Ancestry gives customers a Certiﬁcate of
Ancestry and provides online resources, such as book lists and
embassy information, for customers to connect with their “genetic
cousins” in Africa. Clinical trials may give no resources beyond basic
tests to understand a drug’s safety and efﬁcacy. In all cases, political
reputations mediate researchers’ ability to gain access to research
subjects and amass larger markets. Researchers play on these
differences to promote their own vision of biosociality. How
researchers build their ethics and interpret their social responsi-
bility is thus deeply entwined with social and political consider-
ations such as the coherence between subject and researcher
identity and racial cognizance, but also economic concerns like
proﬁtability.
Genomicists also use subject self-identiﬁcation as a standard
sampling procedure, because they believe this best respects
minority self-determination. Subject self-identiﬁcation is the ﬁrst
step in interfacing a research population. Regarding multi-
population studies, Harvard Medical School’s David Reich
explained:
We ask them: “What is your self-described ancestry?” And I
have a list of things that they can ﬁll out. They will say, “Euro-
pean American,” “AfricaneAmerican,” “Latino American,”
“Japanese American,” etc.
For studies focused on one population, researchers alternately
vet participants by having them identify their grandparents’
origins. Researchers said they prefer self-identiﬁcation (marking
boxes, writing in responses, or both) to eyeballing (registeringa subject’s ancestry by the researcher’s impression), because it best
respects the research subject’s dignity. They were especially vocal
about minority self-identiﬁcation, most using the language of “self-
determination” or refusal to “tell people who they are” to describe
its signiﬁcance to the research process. Researchers spoke of self-
identiﬁcation as a subject’s right in light of the heinous legacy of
racist racial biomedicine, though as critics have argued self-
identiﬁcation according to a pre-selected list also sediments the
autonomy of the scientist to racially categorize (Outram & Ellison,
2006) and to create taxonomy without government oversight
(Bliss, 2012).
Approaching their biomedical choices reﬂexively, these
researchers feel that subject self-identiﬁcation is enacted in the
interest of antiracist values ﬁltered through the constraints of
genomic protocols. Subject self-identiﬁcation introduces overall
ﬁeld-wide inconsistency thereby reducing biomedical rigor. In
other words, there is no scientiﬁc beneﬁt to promoting this
approach. Instead, recalling how they would like to be treated
(either as a minority or as they imagine a minority would), these
researchers said that engaging minority groups on their own terms
is more important than creating an objective research protocol.
Researchers believe maintaining a subject self-identiﬁcation policy
will build trust and lasting relationships with the communities they
feel deserve the utmost attention.Tackling health disparities and race
While most researchers do not claim to know the exact root of
health disparities, all believe genomics will increasingly play
a central role where other ﬁelds have failed. Though researchers
might want to start with strict genomic populations, with
minority health research there is an even greater impetus to make
sampled populations, genomic populations, and target markets
correspond. So while these scientists use self-devised taxonomies,
they increasingly seek answers to racial health disparities in
dominant cultural terms. In fact, their sense of what comprises the
category of “minority” and “minority health” rests on the patterns
of social stratiﬁcation that the U.S. government aims to address
with its Census taxonomy. I consistently heard scientists shuttle
between their own preferred terms, the government’s terms, and
the color-coded terms that they avoid when designing their own
studies. Slippages like these point to greater conceptual ﬂimsiness
between what is perceived as biological versus genomic, and
between goals for research inclusion and inclusion in public
health.
Despite their discomfort with extramural notions of race,
scientists make exceptions for use of racial taxonomy as a heuristic
in research that covers health disparities. Computational biologist
Mark Daly explained their broader systemic concerns:
We can substitute racial labels in a purely genetic study with
actual hard data now, but we can’t do that when we’re looking
completely across the board and in terms of how people are
treated and what access they have had tomedical care and what
access they have had to early life advantages, nutrition and so
forth.
Scientists like Daly overwhelmingly supported the use of racial
taxonomy in measures of the biological effects of racial discrimi-
nation (see, for example, Risch, 2006; Torres & Kittles, 2007).
Due to their commitments to minority health, nearly all the
scientists who spoke out against propagating a genetic concept of
race said they do use a racial taxonomy in their clinical or epide-
miological work. For example, Elad Ziv of the University of
California-San Francisco stated:
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people think of themselves to some degree. So you can get this
information and it turns out it correlates with a lot of diseases,
for various reasons, as a functional thing.
Genomicists emphasized the need to calibrate classiﬁcations to
the wider system of health research, describing a vast epidemio-
logical body of research that precedes genomics. Many of the
researchers I interviewed celebrate the ﬁeld’s ability to join basic
research with this racialized discourse. Other genomicists
expressed the belief that racism creates a biological feedback loop
in the body, therefore racial taxonomy can have direct biological
signiﬁcance. Some argued that “the lifespan of discrimination and
racism based on skin color,” as Kittles put it, justiﬁed the use of
racial heuristics.
I found that researchers are adopting social epidemiological
methods to add to their genomic health disparities research. New
lines of funding and collaboration that governments have formed
with labs that work on the biology of race support this biosocial
framework. For instance, in the U.S., the National Institutes of
Health partners with “Historically Black Universities,” and in 2010
launched a global African genome project that will require new
biotech and pharmaceutical innovations from these very experts.
While genetic epidemiology has often bridged the biological and
social gap in dealing with racial health disparities, the push to
expand genomics to encompass health disparities research is
happening at its primary molecular labs and sequencing centers.
Harvard and Massachusetts General Hospital’s Center for Geno-
mics, Disparities and Vulnerable Populations, Howard’s National
Human Genome Center, and the National Human Genome Research
Institute’s National Intramural Center for Research on Genomics
and Global Health are some examples. These centers make up
a network of labs dedicated to using gene-environment models,
where race is placed at the center of genomic inquiry. The limit of
this new research model is that genomic research into environ-
mental factors focuses on lifestyle and health behaviors, stress, and
other factors pertaining to individual health rather than the social
environment or sociological processes of health.
Elite researchers are also ﬂuent in a social theory idiom, even
comfortable with sociological jargon. Time and time again, they
emphasized that “race is a social construct” and, as one company
website has phrased it, race “includes both a cultural and biological
feature of a person or group of people” (DNAPrint Genomics, 2008).
As I observed, a large majority of these researchers were actively
deliberating racial descriptors in the lab and for institutional policy.
Social and racial justicewas important to the vision theyhave for the
ﬁeld’s development. For example, the National Institutes of Health
Director Francis Collins said, for an ideal study, in addition to
socioeconomic status, educational level, and other contextual
information, “realistically you would want to know for every
participant, okay, what do they self identify with as far as race or
ethnic group?” Collins and others have made public calls for
expanding the biomedicine’s scope in an epidemiological direction,
further fusing genomicmethodswith a speciﬁc biosocial vision of an
antiracist future (see, for example,Manolio, Bailey-Wilson,&Collins,
2004). Again, the limits of this vision are that researchers over-
simplifywhat “social”means in their accountsof social construction.
As one scientist put it, “race is the social construction of who you
are,”evincingan individualized conceptof identityconstruction that
ignores structural inequality and processes of racial ascription.Correcting taxonomies
Since the ﬁeld has yet to be surveyed on their use of ofﬁcial
taxonomies, and the publication record reveals myriad systems, Idecided to investigate how taxonomies get made. Remarkably,
despite the mandate to use ofﬁcial classiﬁcations, I found
researchers devise their own classiﬁcations based on their personal
views about race and racial dialogue with their peers. I also found
researchers to be critical about the classiﬁcation process and, thus,
resistant to the government’s attempts at oversight (Bamshad &
Guthery, 2007). By correcting taxonomies, researchers show an
engagement in political debates that goes far beyond the genomic
job description. They manage taxonomies in ways that are not
simply driven by objective scientiﬁc interests.
The researchers interviewed indicated that, unless they are
involved in a consortium project, they are the ones who determine
the taxonomies that structure their sampling procedures.
Researchers showed me rosters with which they delimited subject
self-identiﬁcation. They use classiﬁcations believed to be racially
sensitive and try to develop a consistency within their own lab’s
sampling protocols. I even observed this replacement of ofﬁcial
standards in two government-based labs.
Despite this autonomous posture, these researchers pointed to
the ways their choices have been shaped by external factors. First,
as discussed above, epidemiological studies use taxonomies that ﬁt
with prior epidemiological systems. Generally, epidemiologists
seem more open to a racially approximate taxonomy, such as
a continental system, if it means their research will be integrated
with that body of research (Bliss, 2012). Second, researchers
examine their classiﬁcations in light of broader political consider-
ations. When I asked researchers to explain what constitutes
a “best” descriptor, contrary to a strict data-driven type of response
all spoke of political sensitivity. This was true for scientists more
comfortable with a priori descriptors, such as genomic epidemiol-
ogists, and more statistically focused scientists who avoid using
a priori categories. For example, Lynn Jorde, the Populations and
ELSI Co-Chair of the International HapMap Project and a developer
of fundamental research methods, said:I avoid using [certain terms] because it immediately incites in
some individuals negative feelings. . . Like the term Caucasian
has this interesting history that has its roots in some real racist
thinking, as I am sure you know. I think 99.9% of the people who
use the term have no idea that it does. It’s kind of like the term
Gypsy. Most people use the term Gypsy not realizing that again
it comes from adwell, it was assigned to “those people” (to
Egypt) and it might be insulting in some cases. And I think the
same is true with Caucasian.
Most think that geographic terms make superior descriptors,
because they are good at imparting the primacy of the environment
in genomic processes, and less politically charged than other kinds
of terms. They believe that geographic terms like “Sub-Saharan
African” provide a neutral alternative to colorized terms like
“black.” They are aware that these terms have a social context and
use them to meet their biosocial needs.
Importantly, all but one of these leading researchers spoke
against standardization in the ﬁeld. As the Broad Institute’s David
Altshuler said: “If you agreed on labels, that would kind of be
problematic, as you’d be endorsing them in some way.” Though
stressing the importance of minority inclusion, these researchers
feel that they can and should be trusted to make the call respective
to each research problem. They maintain a heuristic approach to
sampling, because they believe genomic knowledge of the human
is more accurate than social forms.
Taking a reﬂexively biosocial stance, these researchers
explained the need to correct public misconception about
government standards. The leader of the private effort to map the
human genome, Craig Venter, said:
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have any, to try and inﬂuence the world around us. For me it is
very hard to be in truly a modern society looking at the past
fore-history of our species and not to be upset, be ashamed of it,
extremely bothered by it.
Venter was sure that genomics would eventually produce
a medically relevant taxonomy that people would biosocialize
around. The University of Washington’s Michael Bamshad similarly
refused what he saw as a ﬂawed social rationale: “It makes no sense
tome as towhy I would group a people based on skin pigmentation
alone.” Bamshad’s research has attempted to prove the variability
of correspondence between genomic and racial taxonomy
depending on the markers used to measure human difference, and
provide policy recommendations for moving beyond the U.S.
federal taxonomy (see, for example, Bamshad, 2005; Bamshad
et al., 2003). As a member of the editorial board of the American
Journal of Medical Genetics and co-author of a leading biomedical
textbook, Medical Genetics, he has been an inﬂuential ﬁgure in the
debate over racial taxonomy. All but one of the elites I interviewed
had participated in a public conference on race policy and genomics
in the year leading up to our ﬁrst meeting. Most of them had
organized such conferences in the past and were involved in
ongoing efforts to bring the ﬁeld’s knowledge to minority
community forums. These researchers display a conscious intent to
use genomics to dispel racial myths.
Attention to the implementation of ofﬁcial taxonomies simul-
taneously reveals the most powerful taxonomies in a given
historical moment and the way their application hinges on
a biosocial ethic that researchers themselves construct. Researchers
must identify with such standards or ﬁnd them reﬂective of their
current value system in order to put them into practice. Beliefs
about whom researchers should research will produce alternate
taxonomies, the basis for future standards. Shifting standards will
dialectically infuse social experiences that researchers have within
the ﬁeld and across society, creating new frameworks for inter-
preting race.Conclusion
Taking researcher biosociality seriously permits a novel anal-
ysis of genomics, biomedicine, and race. The interplay between
experiences, values, and taxonomies reveals racial knowledge to
be negotiated with more complex interests than appear at ﬁrst
glance. Genomic elites study race, in part, because they feel that
knowledge about race is valuable to them personally and socially.
They use minority inclusion, social epidemiological tactics, and
self-identiﬁcation to create a biosocial reality that serves values
and ethical goals that are common in contemporary society.
Researchers identify with and as minorities, thus interpreting
their actions as aiding the cause of racial justice. At the same
time, they are transformed by the research they produce. They
practice a reﬂexive form of biosociality in which they actively
work to refashion ideas based on the kind of biosocial future they
want for society. Yet, in privileging a heuristic approach to
taxonomy construction and investigation into race, researchers
keep race at the center of genomic research. Further, they call for
more research and research freedom within the ﬁeld, so that
genomics can one day solve society’s problem of race. Instead of
accepting oversight from the government, these researchers view
the future as one where the ﬁeld’s biological knowledge about
race will serve as a policy corrective and have broad hegemonic
appeal.
While it is important that scientists acknowledge the political
salience of race in their lives and their social worlds, there areproblems with the reﬂexive biosociality discussed here. The case of
race in genomics helps bring a number of issues into view. First,
when scientists appeal to their own experience and understand-
ings, partial or stereotypical ideas can be uncritically put to the
efforts of research equality. Here, we have seen scientists creating
ambivalent research practices with race, including rejecting ofﬁcial
taxonomies while using personally valued lay categories to
promote minority inclusion. Race stands to be reiﬁed as genetic
whenever it is used to structure and communicate genomic
research and evidence, therefore categories that are imported from
the social sphere must be carefully explained and deﬁned. Second,
scientists can reproduce inequality by creating alternatives that are
not so different. Even when scientists alter ofﬁcial taxonomies to
disseminate corrective taxonomies, their taxonomies lend an
imprimatur of science to what are still socially derived taxonomies.
In these cases, genomic comparisons between socially constructed
groups must be qualiﬁed. When scientists engineer taxonomy
toward inclusionary purposes, awareness of the difference between
genomic populations and social populations also must be main-
tained. Finally, by enacting a reﬂexivity focused more on the
researcher’s immediate social world, other spheres of value may go
unaddressed. This leads to a narrowing of practice and a silencing of
alternative strategies. This is most clear in the way the genomic
paradigm has displaced sociological approaches to understanding
race. Many scientists who take issue with the social inequalities of
race never create measures for those very social inequalities, such
as the quality of neighborhoods, living conditions, healthcare, and
other aspects of the built environment. Even when scientists
incorporate social epidemiological indicators, they focus on health
behaviors, lifestyle, and other habits that ignore the broader social
context of inequality.
At present, race consciousness is the ethical norm in genomics.
This mirrors the path of identity politics in the U.S., as reﬂexivity
has come to replace colorblindness. However race consciousness
creates its own problems when it is practiced in the biomedical
context, such as improper treatment and dubious associations
between race and biomedicine, inaccurate conceptions of race and
health disparities, the ﬁxation of racial proﬁling in medicine, and
the establishment of market incentives that cause harm (Epstein,
2007). Thus it is important that genomic biosociality, and all
researcher biosociality, is carefully examined. With a clearer
picture of the kind of sociality new avenues in biomedical research
bring about, a more critical program of knowledge production can
begin. Likewise, a greater understanding of the relationship
between race and biosociality may set us on the path to a more just
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